BDTX (59) VYGR (15) LENZ (44) TVGN (40) ⌘ Pro Terminal →

enGene Therapeutics Inc. (ENGN) — RQD Stock Rating Cockpit

$1.53 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.53

enGene Therapeutics Inc. (ENGN) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $102.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ENGN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ENGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, enGene Therapeutics Inc. (NASDAQ: ENGN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.53 (0.00% 1D, market cap $102.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ENGN ranks #714 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ENGN compare to BDTX and VYGR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ENGN carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BDTX (Black Diamond Therapeutics Inc.) holds a C- grade (59/100 RQD, P/E N/A, ROIC 10.8%, cap $106.9M) and VYGR (Voyager Therapeutics Inc.) posts a E grade (15/100 RQD, P/E N/A, ROIC -35.0%, cap $108.4M). Among the 5-stock peer group, ENGN leads on earnings multiple (N/A) while BDTX leads on capital efficiency (10.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ENGN?

▼

Per ENGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-10-31, CIK 0001980845), enGene Therapeutics Inc. generated $0 in revenue, -$117.3M in net income, and -$100.7M in free cash flow against $337.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.53 (-0.19%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ENGN)Realized 20D OHLCV Swing Band: ±11.8%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY ENGN SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 37 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.70-7.1% Next Q

Q2 (-2Q)

Grade E$1.58+0% Next Q

Q3 (-1Q)

Grade E$1.58-3.2% Next Q

Current

Grade E$1.53-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ENGN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ENGN currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.79) and Max Pain ($1.61) forces dealer call-delta covering toward $12.86.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ENGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ENGN Beats Next Quarter EPS Consensus (Jan 29, 2027) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

3730 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $1$1.53H: $12

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on ENGN

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (28)

8/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like ENGN

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ENGN)

✓Walkthrough of ENGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ENGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -79.89%🛡️ HOLDING TREND SUPPORT

2026-11-02O $1.58H $1.58L $1.53C $1.53VOL 690.4K

RES: $2.19SUP: $1.52SMA50: $1.79SMA200: $4.33

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ENGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ENGN Butterfly Map → + Track ENGN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ENGN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ENGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ENGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ENGN)

Health Care Rank #714 of 1016 ⚔️ BDTX vs ENGN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ENGN vs. BDTX, VYGR, LENZ, TVGN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, enGene Therapeutics Inc. (ENGN) ranks #714 by composite RQD confidence (34/100, grade E) and #659 by equity capitalization ($102.5M). Within this direct 5-issuer industry benchmark cohort, ENGN leads on earnings valuation at N/A trailing P/E, while BDTX leads on capital efficiency and profitability with 10.8% ROIC and — gross margin. BDTX currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with ENGN at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ENGN ACTIVE enGene Therapeutics Inc.	E	34/100	—	—	-35.0%	0.00%	$102.5M	Benchmark Subject
BDTX Black Diamond Therapeutics Inc.	C-	59/100	—	—	10.8%	-4.30%	$106.9M	/bdtx-vs-engn →
VYGR Voyager Therapeutics Inc.	E	15/100	—	—	-35.0%	-2.27%	$108.4M	/vygr-vs-engn →
LENZ LENZ Therapeutics Inc.	D	44/100	—	96.0%	-27.8%	-12.61%	$109.7M	/lenz-vs-engn →
TVGN Tevogen Inc.	D-	40/100	—	—	-35.0%	-2.48%	$95.2M	/tvgn-vs-engn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-10-31 • CIK 0001980845

In its most recent audited fiscal period (FY2025, filed 2025-10-31), enGene Therapeutics Inc. (ENGN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$117.3M, operating cash flow of -$99.2M, and free cash flow of -$100.7M (-104.7% YoY). On the balance sheet, ENGN closed FY2025 with $337.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-10-31	$0	-$117.3M	-$99.2M	-$100.7M	$337.1M	—
FY2024 (FY)	2024-10-31	$0	-$55.1M	-$48.3M	-$49.2M	$285.9M	—
FY2023 (FY)	2023-10-31	$0	-$99.9M	-$24.7M	-$24.7M	—	—

3. ENGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ENGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ENGN compare to BDTX and VYGR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ENGN?

Where is ENGN trading relative to its 50-day, 200-day, and 52-week technical levels?

ENGN last traded at $1.53 (0.00% on volume of 1,197,769 shares), positioning the stock -14.53% below its 50-day simple moving average ($1.79) and -64.67% below its 200-day simple moving average ($4.33). Across its 52-week range of $1.40 to $12.25, ENGN sits at the 1.2% percentile with a 14-day RSI of 37.0 (NEUTRAL RANGE) and an implied next-earnings move of ±11.8% ($1.35 to $1.71).

ENGN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ENGN stock right now?

enGene Therapeutics Inc. (ENGN) currently earns a Roarable Rating of E (Strong Sell — SELL) with 34/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is ENGN's 12-month price target and RQD AI Jury consensus?

ENGN's 12-month base price target is $1.36 (range $1.06 to $12.86), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ENGN RQD Cockpit ENGN 12M Forecast ENGN Earnings & Move ENGN Dividends & DRIP ENGN Insiders & 13F ENGN Whale Options ENGN Profit Sankey ENGN News & Why

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ENGN — enGene Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:44:04Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ENGN scores 34 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars: the Fundamental Cash Engine scores 7/20 (ROIC of -35% and FCF yield of 0%); Whale 13F Flow scores 3/20; Insider Conviction scores 5/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit scores 9/20 (Beta of 1.0); and the Forensic Balance Sheet scores 10/20 (Altman Z of 2.5, Piotroski F of 2/9, Debt/Equity of 0.5).

For a prospective investor, the weakest pillars carry the most weight. The cash engine and institutional flow pillars point to a business that is not yet generating returns on capital and is not attracting meaningful accumulation from institutional holders per the rating's inputs. The forensic balance sheet score is moderate rather than strong: the Piotroski F-Score of 2 out of 9 signals weak fundamental quality, while the Altman Z of 2.5 and Debt/Equity of 0.5 reflect a company that is not heavily levered. The rating's upside case rests mainly on balance-sheet survival and any future clinical or commercial milestones not captured in this source data; valuation tradeoffs are severe given a market cap of $102.5M against reported net losses in every provided period.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-123.2M	$-117.3M	N/A	$-100.7M	$36.6M	N/A
FY 2024	$0.0M	$-62.3M	$-55.1M	N/A	$-49.2M	$62.3M	N/A
FY 2023	$0.0M	$-26.1M	$-99.9M	N/A	$-24.7M	N/A	N/A

Per the SEC financials, the company reported operating losses in all three periods and no revenue. Margins are 0% on gross, operating, and net bases per the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity of 0.5. Cash declined from $62.3M in FY 2024 to $36.6M in FY 2025 as free cash flow remained negative at $-100.7M.

Recent Catalysts & News Wire Analysis

Per the news feed, recent items include a Seeking Alpha piece on preclinical data and clinical case studies for incorporating surfactant bladder rinse into treatment (2026-10-19), a Business Wire announcement of a KOL webinar on October 15, 2026, and an H.C. Wainwright note maintaining a Buy rating with a target price of $4. Other items are aggregator pieces (Yahoo Finance Australia, TradingView, Simply Wall St, Moomoo) without additional substantive content in the source data. All news items are tagged YELLOW with impact label MARKET WIRE. Risk watch items include the continued operating losses and a share price of $1.53 near the low end of its 52-week range of $1.4 to $12.25 (change of -3.16%). Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Open Questions

What are the company's products, clinical pipeline stage, and expected milestones, and how do they relate to the surfactant bladder rinse data referenced in the news feed?
What is the current cash runway given $36.6M in cash against FY 2025 free cash flow of $-100.7M?
Why are debt and EPS reported as N/A, and what is the capital structure behind the Debt/Equity of 0.5?
What drove the net loss in FY 2023 of $-99.9M when operating loss was $-26.1M?
What is the basis for the H.C. Wainwright Buy rating and $4 target price, given that no analyst data is provided?

ENGN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for enGene Therapeutics Inc. (ENGN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ENGN Debate Forum (3) ↓

🟡 MARKET WIRE Seeking Alpha • 7h ago

enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment - Slideshow (NASDAQ:ENGN) 2026-10-19

Seeking Alpha report covering enGene Therapeutics Inc. (ENGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance Australia • 10h ago

enGene Therapeutics Inc. (ENGN) Seasonal returns chart

Yahoo Finance Australia report covering enGene Therapeutics Inc. (ENGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 13h ago

enGene Therapeutics Inc. Estimates – NASDAQ:ENGN

TradingView report covering enGene Therapeutics Inc. (ENGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 16h ago

enGene Therapeutics (Nasdaq:ENGN) - Stock Analysis

Simply Wall St report covering enGene Therapeutics Inc. (ENGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 19h ago

H.C. Wainwright Maintains EnGene Therapeutics(ENGN.US) With Buy Rating, Maintains Target Price $4

Moomoo report covering enGene Therapeutics Inc. (ENGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Business Wire • 22h ago

enGene to Host KOL Webinar on October 15, 2026

Business Wire report covering enGene Therapeutics Inc. (ENGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Relmada Therapeutics, Inc. (RLMD) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering enGene Therapeutics Inc. (ENGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Equillium, Inc. (EQ) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering enGene Therapeutics Inc. (ENGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ENGN Bull vs. Bear Conversation Board — What's Your Call at $1.53?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ENGN 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.35 (-11.8%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ENGN (E • RQD 34/100) a Buy at $1.53?

Welcome to the ENGN (enGene Therapeutics Inc.) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.22 (-20.3%)

Spot @ $1.53

Pump the brakes on ENGN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ENGN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless enGene Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.96 (+28.1%)

Spot @ $1.53

ENGN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ENGN, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $1.53 (52-wk range $1.40 - $12.25), any beat on forward guidance forces shorts and underweight funds to chase.